VRTX·Vertex Pharmaceuticals Incorporated
VRTX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.27 | - | - |
| Q2'26 | $4.82 | $4.73 | -2.0% |
| Q1'26 | $4.39 | $4.47 | +1.7% |
| Q4'25 | $5.17 | $5.03 | -2.7% |
| Q3'25 | $4.58 | $4.80 | +4.9% |
| Q2'25 | $4.25 | $4.52 | +6.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.5B | - | - |
| Q2'26 | $3.3B | $3.3B | +1.1% |
| Q1'26 | $3.1B | $3.0B | -3.4% |
| Q4'25 | $3.2B | $3.2B | -1.5% |
| Q3'25 | - | $3.1B | - |
| Q2'25 | - | $3.0B | - |
VRTX|Monthly Returns
Market Data
VRTX Stock Snapshot
- Market cap
- 143.22B
- P/E ratio
- 32.5
- Day range
- $544.48 – $556.99
- News sentiment
- 53/100 · Neutral
- Analyst target
- $569.54 (+4.3%)
- Consensus
- Buy · 37 analysts
Vertex Pharmaceuticals Incorporated screens well technically, with price sitting near its 52-week high. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What VRTX's own history says about today's numbers
- Realized volatility (21d)
- 34.3% 65th pct
- Below its peak
- 0.0%
- vs 200-day average
- +20.0%
- Up days (1y)
- 48%
Vertex Pharmaceuticals Incorporated is currently running 34.3% annualised volatility over the last 21 sessions. Measured against VRTX's own 13 years of daily returns rather than a market-wide average, that is the 65th percentile — a little above its own norm, against a typical reading of 29.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
VRTX is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -25.1%, with the deepest at -41.7% in 2016 — so highs have historically been given back before they were extended.
Price sits +20.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 83rd percentile — a wider gap than this stock usually carries. Over the past year VRTX closed higher on 48% of sessions, and it is currently 4 sessions into a rising streak.
On September specifically: over 13 years of records, VRTX finished the month higher 2 of 13 times, with a median return of -3.0% and an average of -2.2%. Its strongest month historically has been June at +5.2% on average, its weakest September at -2.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: VRTX has opened more than 2% away from the prior close in 118 of 3,268 sessions (3.6% of the time), with the largest gaps running +48.0% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, VRTX moved an average of 3.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.6% and a largest of +7.7%.
All figures computed from 3,269 daily closes between 2013-09-05 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against VRTX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of VRTX's sector?
Vertex Pharmaceuticals Incorporated sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, VRTX ranks 4th of 15 tracked industries, weakening.
- Sector rank
- #2 of 11
- Sector state
- Weakening
- Sector rotation score
- 90
- Industry rank
- #4 of 15
VRTX Competitive Positioning
- VRTXyou're hereVertex Pharmaceuticals Incorporated$143.2B-0.02%
- REGNRegeneron Pharmaceuticals, Inc.$87.7B0.00%
- MRNAModerna, Inc.$58.6B-0.37%
- BNTXBioNTech SE$26.1B+1.06%
- TECHBio-Techne Corporation$11.3B-0.11%
- DNAGinkgo Bioworks Holdings Inc.$487.5M-0.14%